WO2000070085A3 - Procede pour determiner l'effet de differents agents chimiotherapeutiques et/ou d'une radiotherapie sur des affections malignes, et procede de selection d'agents therapeutiques actifs pour le traitement de ces affections - Google Patents

Procede pour determiner l'effet de differents agents chimiotherapeutiques et/ou d'une radiotherapie sur des affections malignes, et procede de selection d'agents therapeutiques actifs pour le traitement de ces affections Download PDF

Info

Publication number
WO2000070085A3
WO2000070085A3 PCT/DE2000/001444 DE0001444W WO0070085A3 WO 2000070085 A3 WO2000070085 A3 WO 2000070085A3 DE 0001444 W DE0001444 W DE 0001444W WO 0070085 A3 WO0070085 A3 WO 0070085A3
Authority
WO
WIPO (PCT)
Prior art keywords
malignant diseases
effect
radiation therapy
chemotherapeutic agents
detecting
Prior art date
Application number
PCT/DE2000/001444
Other languages
German (de)
English (en)
Other versions
WO2000070085A2 (fr
Inventor
Peter Daniel
Timo Hillebrand
Bernd Doerken
Peter Bendzko
Original Assignee
Theragen Molekularmedizinische
Peter Daniel
Timo Hillebrand
Bernd Doerken
Peter Bendzko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theragen Molekularmedizinische, Peter Daniel, Timo Hillebrand, Bernd Doerken, Peter Bendzko filed Critical Theragen Molekularmedizinische
Priority to EP00941910A priority Critical patent/EP1181394A2/fr
Priority to AU56720/00A priority patent/AU5672000A/en
Publication of WO2000070085A2 publication Critical patent/WO2000070085A2/fr
Publication of WO2000070085A3 publication Critical patent/WO2000070085A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé permettant de déterminer l'effet de différents agents chimiothérapeutiques et/ou d'une radiothérapie sur des affections malignes, selon lequel on définit les profils d'expression de gènes associés à des tumeurs et/ou à la croissance cellulaire et/ou à l'apoptose et/ou les différences (mutations) individuelles dans les séquences de ces gènes. Des modifications liées à l'utilisation des agents chimiothérapeutiques et/ou de la radiothérapie sont identifiées, représentées et soumises à une évaluation diagnostique. L'invention concerne en outre un procédé permettant de sélectionner des agents thérapeutiques efficaces pour le traitement d'affections malignes. L'état de gènes impliqués dans le cycle cellulaire et/ou le gène cible associé à l'apoptose ou de produits géniques de ceux-ci dans des liquides corporels, des cellules et/ou des organes est déterminé et des agents thérapeutiques correspondants sont évalués du point de vue diagnostic en ce qui concerne leur effet. Dans un mode de réalisation préféré, l'expression des gènes bax et p53 ou leurs mutations sont examinées et les informations qui en découlent sont utilisées pour la prise de décision thérapeutique concernant spécifiquement un individu souffrant d'une leucémie ou d'une autre affection maligne.
PCT/DE2000/001444 1999-05-14 2000-05-10 Procede pour determiner l'effet de differents agents chimiotherapeutiques et/ou d'une radiotherapie sur des affections malignes, et procede de selection d'agents therapeutiques actifs pour le traitement de ces affections WO2000070085A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP00941910A EP1181394A2 (fr) 1999-05-14 2000-05-10 Procede pour determiner l'effet de differents agents chimiotherapeutiques et/ou d'une radiotherapie sur des affections malignes, et procede de selection d'agents therapeutiques actifs pour le traitement de ces affections
AU56720/00A AU5672000A (en) 1999-05-14 2000-05-10 Method for detecting the effect of different chemotherapeutic agents and/or radiation therapy in malignant diseases and method for selecting more effective therapeutic agents for the therapy thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19922052.2 1999-05-14
DE19922052A DE19922052A1 (de) 1999-05-14 1999-05-14 Verfahren zum Nachweis der Wirkung von unterschiedlichen Chemotherapeutika und/oder einer Strahlentherapie bei malignen Erkrankungen sowie Verfahren zur Auswahl wirkungsvoller therapeutischer Mittel zu deren Therapie

Publications (2)

Publication Number Publication Date
WO2000070085A2 WO2000070085A2 (fr) 2000-11-23
WO2000070085A3 true WO2000070085A3 (fr) 2001-08-09

Family

ID=7907938

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2000/001444 WO2000070085A2 (fr) 1999-05-14 2000-05-10 Procede pour determiner l'effet de differents agents chimiotherapeutiques et/ou d'une radiotherapie sur des affections malignes, et procede de selection d'agents therapeutiques actifs pour le traitement de ces affections

Country Status (4)

Country Link
EP (1) EP1181394A2 (fr)
AU (1) AU5672000A (fr)
DE (1) DE19922052A1 (fr)
WO (1) WO2000070085A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5813908B2 (ja) * 2004-04-09 2015-11-17 ジェノミック ヘルス， インコーポレイテッド 化学療法剤に対する応答を予測するための遺伝子発現マーカー
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CN101449162B (zh) 2006-05-18 2013-07-31 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
EP2474624B1 (fr) 2011-01-05 2016-08-17 Daniela Kandioler Prédiction de la réponse dans le traitement du cancer (thérapie du cancer adaptée p53)
EP2474625B1 (fr) * 2011-01-05 2016-11-02 Daniela Kandioler Procédé de détermination du statut du gène p53 d'une tumeur
US20240191303A1 (en) * 2021-04-05 2024-06-13 Brown University Methods for optimizing the treatment of colorectal cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053103A1 (fr) * 1997-05-21 1998-11-26 Clontech Laboratories, Inc. Ensembles d'acide nucleique

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053103A1 (fr) * 1997-05-21 1998-11-26 Clontech Laboratories, Inc. Ensembles d'acide nucleique

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; August 1998 (1998-08-01), TAI YU-TZU ET AL: "BAX protein expression and clinical outcome in epithelial ovarian cancer.", XP002161066, Database accession no. PREV199800406324 *
FINDLEY HARRY W ET AL: "Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia.", BLOOD, vol. 89, no. 8, 1997, pages 2986 - 2993, XP002161054, ISSN: 0006-4971 *
JOURNAL OF CLINICAL ONCOLOGY, vol. 16, no. 8, August 1998 (1998-08-01), pages 2583 - 2590, ISSN: 0732-183X *
KRAJEWSKI STANISLAW ET AL: "Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma.", CANCER RESEARCH, vol. 55, no. 19, 1995, pages 4471 - 4478, XP002161055, ISSN: 0008-5472 *
LOWE SCOTT W ET AL: "P53 status and the efficacy of cancer therapy in vivo.", SCIENCE (WASHINGTON D C), vol. 266, no. 5186, 1994, pages 807 - 810, XP002161052, ISSN: 0036-8075 *
MCCURRACH MILA E ET AL: "Bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 94, no. 6, 1997, 1997, pages 2345 - 2349, XP002161053, ISSN: 0027-8424 *
MEIJERINK JULES P P ET AL: "Hematopoietic malignancies demonstrate loss-of-function mutations of BAX.", BLOOD, vol. 91, no. 8, 15 April 1998 (1998-04-15), pages 2991 - 2997, XP002161056, ISSN: 0006-4971 *
REED JOHN C ET AL: "BCL-2 Family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy.", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 60, no. 1, 1996, pages 23 - 32, XP002161051, ISSN: 0730-2312 *
STURM ISRID ET AL: "Analysis of the p53/BAX pathway in colorectal cancer: Low BAX is a negative prognostic factor in patients with resected liver metastases.", JOURNAL OF CLINICAL ONCOLOGY, vol. 17, no. 5, May 1999 (1999-05-01), pages 1364 - 1374, XP000982432, ISSN: 0732-183X *

Also Published As

Publication number Publication date
WO2000070085A2 (fr) 2000-11-23
EP1181394A2 (fr) 2002-02-27
DE19922052A1 (de) 2000-11-16
AU5672000A (en) 2000-12-05

Similar Documents

Publication Publication Date Title
WO2007143752A3 (fr) Cibles pour le pronostic ou la thérapie dans le cancer du sein
HK1077475A1 (en) Compositions and methods for cancer diagnosis and therapy
WO2000070085A3 (fr) Procede pour determiner l'effet de differents agents chimiotherapeutiques et/ou d'une radiotherapie sur des affections malignes, et procede de selection d'agents therapeutiques actifs pour le traitement de ces affections
AU2003293141A1 (en) Methods for identifying risk of breast cancer and treatments thereof
AU2001240909A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU6583700A (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2003070889A3 (fr) Genes specifiques de la prostate et leur utilisation dans la conception ou la therapie
WO2004009112A8 (fr) Utilisation d'urease pour inhiber la croissance de cellules cancereuses
WO2003031572A3 (fr) Polypeptides therapeutiques, acides nucleiques codant ces derniers et methodes d'utilisation
WO2004013313A3 (fr) Acides nucleiques antisens
Bielka et al. Induction of the small stress protein, hsp25, in Ehrlich ascites carcinoma cells by anticancer drugs
HK1111721A1 (en) Sparc promoter mutations associated with drug resistance, and methods associated therewith
CY1110911T1 (el) Ανθρωπινο γονιδιο tsc403
PT1472375E (pt) Produtos génicos expressos diferencialmente em células cancerígenas da mama e seus métodos de utilização
WO2003076578A3 (fr) Polypeptides therapeutiques, acides nucleiques codant pour eux et leur procede d'utilisation
CN107937520A (zh) 与结直肠癌相关的分子标记物、抑制剂、试剂盒和药剂
EP1573069A4 (fr) Genes cibles cancereux amplifies destines au criblage diagnostique et therapeutique
Chapiro et al. Genetic Characterization of B-Cell Prolymphocytic Leukemia (B-PLL): A Hierarchical Prognostic Model Involving MYC and TP53 Abnormalities. on Behalf of the Groupe Francophone De Cytogenetique Hematologique (GFCH) and the French Innovative Leukemia Organization (FILO) Group
Papadimitriou et al. Genomic and Transcriptomic Landscape of Hyper-Apobec Multiple Myeloma
WO2003027632A3 (fr) Utilisation de cellules cancereuses humaines isogeniques aux fins de criblage a haute capacite et de selection de medicaments
Öfner In situ standardised AgNOR analysis: a simplified method for routine use to determine prognosis and chemotherapy efficiency in colorectal adenocarcinoma
Cosset et al. The role of radiotherapy for early stage Hodgkin’s disease: limitations and perspectives
Hummel et al. DNA damage response
WO2004033641A3 (fr) Profilage de l'expression genique du cancer de la vessie
Ringborg Adjuvant chemotherapy: a discussion of some basic principles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000941910

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09979513

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000941910

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000941910

Country of ref document: EP